FOLH1 and neoplasm: The hypothesis of this study is that complementing EBRT and ADT with a single cycle concurrent [177Lu]Lu-PSMA-617 is safe, while providing synergistic anti-tumour effects with limited toxicity and without prolonging overall treatment time, with potential to improve tumour control and quality of life for future patients with N1M0 prostate cancer.